A Warning Letter issued by the US Food & Drug Administration (FDA) to an Indian API manufacturer on 13 July 2015 shows again a clear focus on the missing integrity of data. Specifically, the following issues are addressed:
1. Activities were not recorded at the time they were carried out and original data were deleted:
Entries in the manufacturing protocols were made only days after the relevant activities had been conducted. Further, batches were released before all results were available.
In particular the use of “rough notes” was criticised as these original data were completely destroyed after transfer in the batch records.
2. Due to unauthorised access to data systems, data could be modified or deleted:
Specifically HPLC, GC, and Karl Fischer Titrators were concerned. For instance, for the GC instrument multiple copies of raw data were found in the waste. And there was no password regulation for the data systems…
View original post 100 more words